CutisPharma Acquires Silvergate Pharmaceuticals and Rebrands as Azurity Pharmaceuticals

June 12, 2019

CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.

Buyers
CutisPharma, Inc., NovaQuest Private Equity (QHP Capital)
Targets
Silvergate Pharmaceuticals, Inc.
Industry
Pharmaceuticals
Location
Colorado, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.